In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent.

Abstract

The activity of HQQ-3, a new triazole antifungal agent, was evaluated and compared with those of fluconazole, ketoconazole and terbinafine in vitro and with fluconazole in vivo. HQQ-3 exhibited potent in vitro activity against clinically important fungi. The activity of HQQ-3 against Candida spp. was superior to those of fluconazole and terbinafine and comparable or superior to that of ketoconazole. HQQ-3 retained potent activity against Candida albicans strains with low levels of susceptibility to fluconazole (fluconazole MIC80s range, 4 to >64 microg/ml). Against Cryptococcus neoformans and filamentous fungi, the activity of HQQ-3 was superior to that of fluconazole. HQQ-3 also exhibited potent in vivo activity against murine systemic infections caused by C. albicns and C. krusei. The 50% effective doses against these infections were 0.12 to 1.9 mg/kg of body weight. These result suggest that HQQ-3 may be useful in the treatment of candidiasis.

Cite this paper

@article{Zhao2006InVA, title={In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent.}, author={Jing-xia Zhao and Yingying Cao and Hua Quan and Chao-mei Liu and Qiu-Qing He and Qiu-ye Wu and Ping-hui Gao and Yong-bing Cao and Wen-xia Liu and Yuanying Jiang}, journal={Biological & pharmaceutical bulletin}, year={2006}, volume={29 10}, pages={2031-4} }